Skip to main content
Premium Trial:

Request an Annual Quote

Genset Licenses Chlamydia Sequence to Ricerca; Diagnostic Partner Still Elusive

NEW YORK, July 26 - French genomics company Genset said today it has granted to Ricerca Biosciences an exclusive worldwide license to its chlamydia genome sequence.

The deal gives Ricerca the right to develop therapeutic products with Genset's full-length sequences of Chlamydia pneumoniae and Chlamydia trachomatis. Ricerca also will own rights to all anti-infective drugs that may arise.

In return, Genset will receive an undisclosed equity position in Ricerca along with patents, milestones, and royalties from any drugs and candidates developed by Ricerca.
Genset has already licensed to Wyeth the vaccine rights for its Chlamydia IP, but said that it is holding on to the diagnostic rights until it finds a "suitable partner."


Last month, Genset said that it was to be acquired by Swiss biotech Serono. The acquisition will be put before a Serono shareholder meeting in September.

Meanwhile, Ricerca, of Concord, Ohio, said it is "actively" licensing a portfolio of new anti-infective and oncologic genomic targets and lead candidate molecules for internal drug development.


Click here for more information.




The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.